Table 1 Participant baseline characteristics
Control | Intervention | |
|---|---|---|
N = 73 (%) | N = 73 (%) | |
Age | ||
Median (range) | 66 (32–83) | 66 (34–87) |
Sex | ||
Male | 43 (59) | 35 (48) |
Female | 30 (41) | 38 (52) |
Drugs received | ||
Ipilimumab | 3 (4) | 4 (6) |
Pembrolizumab | 36 (49) | 38 (52) |
Nivolumab | 13 (18) | 11 (15) |
Ipilimumab + nivolumab | 21 (29) | 20 (28) |
ECOG performance | ||
0 | 52 (72) | 49 (69) |
1 | 19 (26) | 19 (27) |
2 | 30 (41) | 38 (52) |
Disease stage | ||
Stage III | 12 (16) | 10 (14) |
Stage IV | 61 (84) | 63 (86) |
Line of therapy | ||
Adjuvant | 13 (18) | 11 (15) |
1st line | 52 (71) | 52 (71) |
2nd line | 6 (8) | 6 (8) |
3rd line | 2 (3) | 4 (5) |